Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Joint Bone Spine
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le samedi 18 janvier 2020
Doi : 10.1016/j.jbspin.2019.10.004
Received : 25 June 2019 ; 
Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients
 

Bruno Fautrel a, b, Manon Belhassen c, d, , Christophe Hudry e, Marie-Christine Woronoff-Lemsi f, g, Laurie Levy-Bachelot h, Eric Van Ganse c, d, Florence Tubach i, j
a Sorbonne universités, UPMC université Paris 06, GRC 08, 75006 Paris, France 
b Rheumatology department, Pitié-Salpétrière university hospital, AP–HP, 75013 Paris, France 
c PELyon, pharmacoépidemiologie Lyon, 69008 Lyon, France 
d HESPER 7425, health services and performance research, university Claude Bernard Lyon 1, 69008 Lyon, France 
e Hôpital Cochin, AP–HP, 75014 Paris, France 
f CHU Besançon, 25030 Besançon, France 
g COMUE UBFC, UMR Inserm 1098, université Franche-Comté, 25030 Besançon, France 
h Merck Sharp & Dohme, 92400 Paris, France 
i Inserm, Institut Pierre Louis d’épidémiologie et de Santé Publique, Sorbonne université, 75013 Paris, France 
j Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), CIC-1421, IPLESP, Hôpitaux Universitaires Pitié Salpêtrière - Charles Foix, AP–HP, 75013 Paris, France 

Corresponding author. Pharmacoepidemiology, faculté d’odontologie, UCBL, 11, rue Guillaume Paradin, 69372 Lyon cedex 08, France.Pharmacoepidemiology, faculté d’odontologie, UCBL11, rue Guillaume ParadinLyon cedex 0869372France
Highlights

A high reduction in US tophus size at M6 is associated with low probability of relapse after stopping gout prophylaxis.
Probability of relapse was increased with a reduction in tophus size<50% (odds ratio 3.35 [95% CI 0.98; 11.44]).
US follow-up may be useful for managing ULT and gout flare prophylaxis.

The full text of this article is available in PDF format.
Abstract
Objectives

To determine whether changes in ultrasonography (US) features of monosodium urate crystal deposition is associated with the number of gouty flares after stopping gout flare prophylaxis.

Methods

We performed a 1-year multicentre prospective study including patients with proven gout and US features of gout. The first phase of the study was a 6-month US follow-up after starting urate-lowering therapy (ULT) with gout flare prophylaxis. After 6 months of ULT, gout flare prophylaxis was stopped, followed by a clinical follow-up (M6 to 12) and ULT was maintained. Outcomes were the proportion of relapsing patients between M6 and M12 according to changes of US features of gout and determining a threshold decrease in tophus size according to the probability of relapse.

Results

We included 79 gouty patients (mean [±SD] age 61.8±14 years, 91% males, median disease duration 4 [IQR 1.5; 10] years). Among the 49 completers at M12, 23 (47%) experienced relapse. Decrease in tophus size50% at M6 was more frequent without than with relapse (54% vs. 26%, P =0.049). On ROC curve analysis, a threshold decrease of 50.8% in tophus size had the best sensitivity/specificity ratio to predict relapse. Probability of relapse was increased for patients with a decrease in tophus size <50% between M0 and M6 (OR 3.35 [95% confidence interval 0.98; 11.44]).

Conclusion

A high reduction in US tophus size is associated with low probability of relapse after stopping gout prophylaxis. US follow-up may be useful for managing ULT and gout flare prophylaxis.

The full text of this article is available in PDF format.

Keywords : Rheumatoid arthritis, Predictive factors, Persistence, Subcutaneous TNF inhibitors




© 2019  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline